Raymond James Downgrades Masimo Corporation to Market Perform

Brokerage firm Raymond James Downgrades its rating on Masimo Corporation(MASI). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by the stock financial advisor at Raymond James was issued on Feb 13, 2017 in a research report to their Investors and Clients.

Masimo Corporation (MASI) made into the market gainers list on Wednesdays trading session with the shares advancing 2.03% or 1.73 points. Due to strong positive momentum, the stock ended at $87.05, which is also near the day’s high of $87.65. The stock began the session at $85.35 and the volume stood at 12,46,292 shares. The 52-week high of the shares is $87.65 and the 52 week low is $33.03. The company has a current market capitalization of $4,389 M and it has 5,04,19,060 shares in outstanding.

Masimo Corporation(MASI) last announced its earnings results on Aug 3, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $172.64M. Analysts had an estimated revenue of $166.02M. Earnings per share were $0.49. Analysts had estimated an EPS of $0.41.

Several Insider Transactions has been reported to the SEC. On Feb 7, 2017, Raad Mark De (EVP & Chief Financial Officer) sold 15,000 shares at $75.00 per share price.Also, On Feb 7, 2017, Jon Coleman (Pres-WW Sales,Pro Svc,Med Affs) sold 6,000 shares at $75.00 per share price.On Feb 3, 2017, Yongsam Lee (EVP & CIO) sold 10,000 shares at $74.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Masimo Corporation is a global medical technology company that develops manufactures and markets non-invasive patient monitoring products. The Company’s core business is measure-through-motion and low-perfusion pulse oximetry monitoring known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive optical blood constituent monitoring optical organ oximetry monitoring electrical brain function monitoring acoustic respiration monitoring and optical gas monitoring. In addition the Company offers Root patient monitoring and connectivity platform the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. The Company also has the Patient SafetyNet remote patient surveillance monitoring system which allows up to 80 patients to be monitored simultaneously through a central station or remotely by care providers through their pagers or smart phones.

Add Comment